StockData
Aldeyra Therapeutics, Inc. logo

Aldeyra Therapeutics, Inc. (ALDX) stock

ALDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.67+0.03 (+4.01%)

Close on Nov 16, 2026Market cap $40.39MP/E –Yield –

Aldeyra Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Aldeyra Therapeutics's total debt was $0 at Jun 30, 2026. For fiscal 2025 it was $15.25M, up 1.5% from the year before. Over ten years it grew 28.4% a year on average. The highest annual figure on record is $15.83M in fiscal 2022.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$15.25M+1.5%
FY2024Dec 31, 2024$15.03M-0.8%
FY2023Dec 31, 2023$15.15M-4.3%
FY2022Dec 31, 2022$15.83M+2.1%
FY2021Dec 31, 2021$15.50M+35.6%
FY2020Dec 31, 2020$11.43M-21.3%
FY2019Dec 31, 2019$14.53M+987.0%
FY2017Dec 31, 2017$1.34M+1.5%
FY2016Dec 31, 2016$1.32M+2.1%
FY2015Dec 31, 2015$1.29M+2.9%
FY2014Dec 31, 2014$1.25M+5.5%
FY2013Dec 31, 2013$1.19M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0-100.0%
Q1 FY2026Mar 31, 2026$15.30M+1.3%
Q4 FY2025Dec 31, 2025$15.25M+1.5%
Q3 FY2025Sep 30, 2025$15.20M-0.5%
Q2 FY2025Jun 30, 2025$15.15M-0.6%
Q1 FY2025Mar 31, 2025$15.10M-0.7%
Q4 FY2024Dec 31, 2024$15.03M-0.8%
Q3 FY2024Sep 30, 2024$15.28M-5.2%
Q2 FY2024Jun 30, 2024$15.24M-4.9%
Q1 FY2024Mar 31, 2024$15.20M-4.5%
Q4 FY2023Dec 31, 2023$15.15M-4.3%
Q3 FY2023Sep 30, 2023$16.12M+388.0%
Q2 FY2023Jun 30, 2023$16.02M+49.1%
Q1 FY2023Mar 31, 2023$15.92M+2.2%
Q4 FY2022Dec 31, 2022$15.83M+2.1%
Q3 FY2022Sep 30, 2022$3.30M-78.6%
Q2 FY2022Jun 30, 2022$10.74M-30.0%
Q1 FY2022Mar 31, 2022$15.59M+53.7%
Q4 FY2021Dec 31, 2021$15.50M+35.6%
Q3 FY2021Sep 30, 2021$15.42M+21.5%
Q2 FY2021Jun 30, 2021$15.34M+10.2%
Q1 FY2021Mar 31, 2021$10.14M-30.9%
Q4 FY2020Dec 31, 2020$11.43M-21.3%
Q3 FY2020Sep 30, 2020$12.69M-11.8%
Q2 FY2020Jun 30, 2020$13.92M+932.3%
Q1 FY2020Mar 31, 2020$14.67M+991.3%
Q4 FY2019Dec 31, 2019$14.53M+987.0%
Q3 FY2019Sep 30, 2019$14.39M+980.3%
Q3 FY2018Sep 30, 2018$1.35M+1.6%
Q2 FY2018Jun 30, 2018$1.34M+1.7%
Q4 FY2017Dec 31, 2017$1.34M+1.5%
Q3 FY2017Sep 30, 2017$1.33M+1.7%
Q2 FY2017Jun 30, 2017$1.33M+1.8%
Q1 FY2017Mar 31, 2017$1.32M–
Q4 FY2016Dec 31, 2016$1.32M–
Q3 FY2016Sep 30, 2016$1.31M–
Q2 FY2016Jun 30, 2016$1.30M–

More Aldeyra Therapeutics figures

See a number that looks wrong?